Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Staphylococcus Aureus Clear all
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00424190
View directory record Official record
Conditions
Bacterial Infections
Interventions
IV Vancomycin plus IV Aztreonam, Ceftaroline
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 20, 2026, 11:07 PM EDT
Terminated Phase 2 Interventional Results available

Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults

NCT00869518
View directory record Official record
Conditions
Staphylococcus Aureus, HIV Infections
Interventions
rifabutin plus trimethoprim sulfamethoxazole, placebo plus trimethoprim-sulfamethoxazole
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection

NCT00801879
View directory record Official record
Conditions
Staphylococcus Aureus, HIV Infections
Interventions
Mupirocin calcium ointment, 2%, Placebo ointment
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 20, 2026, 11:07 PM EDT
Active, not recruiting No phase listed Observational

Immune Resolution After Staphylococcus Aureus Bacteremia

NCT01879761
View directory record Official record
Conditions
Immune Response To Sepsis, Staphylococcus Aureus Infection
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Not applicable Interventional

Rapid Detection of Staphylococcus Aureus in Burn Patients

NCT01140269
View directory record Official record
Conditions
Burns, Sepsis
Interventions
PCR test
Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years to 90 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Sacramento, California • Miami, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

NCT01643941
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, SA4Ag vaccine high dose, SA3Ag vaccine, Blood sample, Placebo, Colonization swab samples
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
7
States / cities
Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 20, 2026, 11:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detection of Staph Colonization in Pre-op Arthroplasty Patients

NCT01648088
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

NCT03181932
View directory record Official record
Conditions
MRSA, Cystic Fibrosis
Interventions
Vancomycin inhalation powder, Placebo inhalation powder
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
6 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
69
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates

NCT00475930
View directory record Official record
Conditions
Staphylococcus Aureus, Community-acquired Infections, Staphylococcal Skin Infections
Interventions
2% chlorhexidine gluconate (CHG) impregnated cloths, Comfort Bath cloths (placebo cloths)
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 35 Years
Enrollment
1,563 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Quantico, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 20, 2026, 11:07 PM EDT
Withdrawn Not applicable Interventional

Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients

NCT01229553
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
decolonization
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
2 Months to 23 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 20, 2026, 11:07 PM EDT
Recruiting Not applicable Interventional

Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

NCT05975671
View directory record Official record
Conditions
Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy, Sepsis, Severe, Septic Shock, Septic Syndrome
Interventions
Multifaceted de-implementation strategy to reduce vancomycin overuse
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
52,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 20, 2026, 11:07 PM EDT
Completed No phase listed Observational

Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus

NCT01141101
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Not applicable Interventional Results available

Individualized vs. Household MRSA Decolonization

NCT01814371
View directory record Official record
Conditions
Staphylococcal Skin Infection, Abscess, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% mupirocin ointment, Bleach Bath (dilute), Hygiene Protocol
Drug · Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

NCT01364571
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
16
States / cities
Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Not applicable Interventional Results available

The Natural History of Community-Associated MRSA Infections and Decolonization Strategies

NCT00513799
View directory record Official record
Conditions
Abscesses, Furunculosis, Staphylococcus Aureus, Staphylococcal Skin Infections
Interventions
Mupirocin ointment, Chlorhexidine showers, Bleach baths (dilute), Intensive education on personal hygiene
Drug · Genetic · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 20, 2026, 11:07 PM EDT
Completed No phase listed Observational

Reducing Perioperative S. Aureus Transmission Via OR PathTrac

NCT04657185
View directory record Official record
Conditions
S. Aureus Transmission, Surgical Site Infection
Interventions
OR PathTrac Feedback Optimization
Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
804 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Georgetown, District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 3 Interventional

A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection

NCT00560599
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus Skin Infections
Interventions
mupirocin and chlorhexidine, household cleaning and disinfection, mupirocin, chlorhexidine, & household cleaning/disinfection
Drug · Behavioral
Lead sponsor
loren g miller
Other
Eligibility
1 Month and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Anaheim, California • Bellflower, California • Harbor City, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 20, 2026, 11:07 PM EDT
Not listed Not applicable Interventional

Probiotics Pilot Project

NCT04247854
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Bacillus subtilis probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 20, 2026, 11:07 PM EDT
Completed No phase listed Observational

Chart Review of Outcome of Treatment for S. Aureus Bacteremia

NCT00304902
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children

NCT02335905
View directory record Official record
Conditions
Hematogenously Acquired Staphylococcus Aureus Osteomyelitis, Bone Infection, Osteomyelitis
Interventions
Ceftaroline Fosamil
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 20, 2026, 11:07 PM EDT
Completed No phase listed Observational

Clinical Priority Program-Bone Infection Registry

NCT01677000
View directory record Official record
Conditions
Bone Infection, Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
AO Clinical Investigation and Publishing Documentation
Other
Eligibility
18 Years to 130 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
5
States / cities
Columbia, Missouri • Rochester, New York • Danville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 20, 2026, 11:07 PM EDT
Terminated No phase listed Observational

Impact of Mupirocin Decolonization on the Nasal Microbiome

NCT02045329
View directory record Official record
Conditions
Nasal Colonization With Staph Aureus
Interventions
Not listed
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 20, 2026, 11:07 PM EDT
Completed No phase listed Observational

An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS

NCT00754273
View directory record Official record
Conditions
Methicillin-resistant Staphylococcal Aureus Pneumonia
Interventions
etest susceptability testing
Other
Lead sponsor
University of Kentucky
Other
Eligibility
Not listed
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 20, 2026, 11:07 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

NCT00695903
View directory record Official record
Conditions
Endocarditis, Bacterial, Infective Endocarditis
Interventions
daptomycin, vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Greenville, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 20, 2026, 11:07 PM EDT